The first experimental COVID-19 vaccine in the U.S.is on track to begin a huge study next month to prove if it really can fend off the coronavirus, its Cambridge-based manufacturer announced Thursday - a long-awaited step in the global vaccine race. The administration has launched a program called "Operation Warp Speed", with the ambitious goal of rolling out a safe and effective vaccine by the year's end.
"We're putting the whole intellect of the world at work to get that shortened as much as possible", he explained. The human trials will involve 1045 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older.
However, Lam said, China and other vaccine developers are faced with many challenges.
Moreover, the vaccine exhibits high productivity and good genetic stability for manufacturing which will help in further evaluation in a clinical trial, according to the research.
The final study, which will include 30,000 people, will be conducted in collaboration with the National Institute of Allergy and Infectious Diseases in the U.S. Its primary goal will be to show the vaccine prevents people from developing symptoms of COVID-19, Moderna said in a statement. And that's where these trials are so unpredictable, ' he said referring to the percentage of new cases occurring in the population at the time.
The plan would offer financial guarantees to pharmaceutical companies, which face big losses if their vaccines are not successful.
President Donald Trump Tweetstorm - The Sunday Edition
He said he generally didn't like "demonizing other people" and instead preferred to talk about policies and solutions to problems. Powell went on to add that "you have to agree" with Mattis' criticism of Trump because "he is insulting us throughout the world".
Moderna's Early, Midstage Coronavirus Update: For the early- and mid-stage studies that are ongoing, Moderna said the original cohorts in the Phase 1 study are in long-term follow-up and enrollment is complete in nine of the 12 cohorts that were subsequently added.
The production of the vaccine will take place in Leiden, the United States and possibly Asia, the company said.
British-based drugmakers AstraZeneca AZN.L and GlaxoSmithKline GSK.L , France's Sanofi SASY.PA , and USA players Pfizer PFE.N , Novavax NVAX.O , Johnson & Johnson JNJ.N and Moderna MRNA.O are among companies trialling vaccines.
S, recombinant, emerged from vaccine constructs created and tested by J&J with Beth Israel Deaconess Medical Center (BIDMC), part of Harvard Medical School, using Janssen's AdVac® and PER.C6® vaccine technology platforms, designed for accelerated vaccine development.
There are now about 10 coronavirus vaccines being tested in humans and experts have predicted that a safe and effective vaccine could take 12 to 18 months from the start of development.